EchoIQ (ASX:EIQ) Surges as Pro Medicus Partnership Expands the Cardiac AI Story

Aditi Sarkar

05 August 2026 03:37 PM AEST

EchoIQ (ASX:EIQ) Surges as Pro Medicus Partnership Expands the Cardiac AI Story

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

EchoIQ shares are gaining 12.32% to AUD 1.55, with the price trading between AUD 1.365 and AUD 1.568.
EchoIQ has secured binding heads of agreement with Pro Medicus, establishing a framework for a strategic investment and a US commercial partnership.
Trading volume is reaching 3,016,688 shares and market capitalisation is standing near AUD 1.15bn.
Definitive pro medicus agreements, us regulatory progress, mayo clinic deployment, reimbursement and commercial revenue are the main checkpoints.

EchoIQ Ltd (ASX:EIQ) is attracting market attention as its shares gain 12.32% to AUD 1.55. The stock is trading within a range of AUD 1.365 to AUD 1.568, while 3,016,688 shares are changing hands. The move is bringing the company’s latest operating and strategic developments back into focus.

The share price is recording 620.93% over one year, placing the current session within a positive longer-term trend. A one-day rise can signal changing expectations, but sustained performance will depend on the company meeting operational milestones and converting activity into revenue and cash flow.

Company Overview

EchoIQ develops artificial-intelligence software designed to assist the detection of structural heart disease and heart-failure risk.

Latest Company Development

EchoIQ has secured binding heads of agreement with Pro Medicus, establishing a framework for a strategic investment and a US commercial partnership. It is also working with Mayo Clinic on a potential route to distribute EchoSolv HF following regulatory clearance, while research is extending into cardio-oncology applications.

Share Price and Market Snapshot

EIQ shares are trading at AUD 1.55, up 12.32% during the session. The price is reaching AUD 1.568 after trading as low as AUD 1.365, while volume is totalling 3,016,688 shares. At the current price, the company is carrying a market capitalisation of approximately AUD 1.15bn. The one-year share-price movement is 620.93%, showing that the latest advance is occurring within a broader trend that may differ from the current session.

What Investors May Watch Next

Definitive pro medicus agreements, us regulatory progress, mayo clinic deployment, reimbursement and commercial revenue. These factors will help determine whether the current share-price interest is supported by improving business execution.

The next formal update may provide a clearer view of revenue quality, cash requirements and delivery against stated milestones. For smaller technology companies, liquidity and capital needs can amplify both positive and negative market reactions.

Risks

The current share-price gain may reverse if expectations move ahead of operating progress.
Customer contracts, product development or regulatory milestones may be delayed or unsuccessful.
Revenue may remain concentrated among a limited number of customers, projects or markets.
Further funding may increase debt or dilute existing shareholders.
Low liquidity and broader technology-sector sentiment may amplify price volatility.

FAQs

Q: Why are EchoIQ shares attracting attention?

A:The shares are gaining 12.32% to AUD 1.55 and are trading as high as AUD 1.568 during the session.

Q: What is the latest development at EchoIQ?

A:EchoIQ has secured binding heads of agreement with Pro Medicus, establishing a framework for a strategic investment and a US commercial partnership. It is also working with Mayo Clinic on a potential route to distribute EchoSolv HF following regulatory clearance, while research is extending into cardio-oncology applications.

Q: What is EchoIQ’s market capitalisation?

A:The company’s market capitalisation is approximately AUD 1.15bn at the current trading price.

Q: What should investors watch next?

A:Definitive pro medicus agreements, us regulatory progress, mayo clinic deployment, reimbursement and commercial revenue.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.